Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile of human leukemic cell line treated with TLR1/2 agonist.

ABSTRACT: Gene expression profile of human leukemic cell line treated with TLR1/2 agonist.

PROVIDER: PRJNA768468 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16201368.fastq.gz	Fastqsanger.gz
	SRR16201369_1.fastq.gz	Fastqsanger.gz
	SRR16201369_2.fastq.gz	Fastqsanger.gz
	SRR16201370_1.fastq.gz	Fastqsanger.gz
	SRR16201370_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 7

Similar Datasets

Gene expression profile of human leukemic cell line treated with TLR1/2 agonist.

Project description:Treatment of MV4;11 cells with CU-T12-9 increased ubiquitination of c-Myc compared to control and correspondingly resulted in reduced K148 acetylation. Chromatin immunoprecipitation coupled to high-throughput sequencing (Chip-Seq) revealed a significant loss of c-Myc occupancy in the genome following TLR1/2 activation with CU-T12-9. As expected, diminished c-Myc binding resulted in gene downregulation of well-establish c-Myc targets. These findings suggest that TLR-mediated K63-linked ubiquitination of c-Myc at K148 inhibits activation of c-Myc by interfering with its acetylation at the same residue.

2023-10-01 | GSE185299 | GEO

Gene expression profile of human leukemic cell line with cMyc mutations

Project description:Gene expression profile of human leukemic cell line with cMyc mutations

| PRJNA768467 | ENA

RNA-seq HepG2 cell line treated with TRPV2 inhinitor or agonist

Project description:HepG2 cell line was co-cultured with 1ml/L Fat emulsion, after 24h treatment with agonist (2-APB) or inhibitor (SKF-96365). RNA-seq was performed.

2023-12-01 | GSE221726 | GEO

RNA-seq HepG2 cell line treated with TRPV2 inhinitor or agonist

Project description:RNA-seq HepG2 cell line treated with TRPV2 inhinitor or agonist

| PRJNA915615 | ENA

miRNA profiling of extracellular vesicled derived from acute lymphoblastic leukemic cell line 697 treated with ActivinA against untreated cells

Project description:Role of ActivinA in the modulation of EV-miRNA cargo in acute lymphoblastic leukemic cell line 697.

2024-06-18 | E-MTAB-14003 | biostudies-arrayexpress

Global gene expression profile of primary human leukemic blasts

Project description:The goal of this study is to define the global gene expression profile of primary leukemic blasts from patients with different forms of myeloid leukemia and different FAB subtypes. Here we report the global gene expression profile of 2 patients with AML FAB M5, 2 patients with AML FAB M7, 3 patients with Down syndrome AML FAB M7 and 3 patients with Down syndrome transient leukemia.

2009-12-29 | GSE19681 | GEO

Leukemic hematopoiesis

Project description:Leukemic hematopoiesis

| PRJNA881262 | ENA

Transcription profiling of human patients with acute myeloid leukemia (AML) were stimulated stimulated with MPL receptor agonist (SB559457) or recombinant human Tpo (rhTpo) for 6 hours

Project description:Biologic characterization of SB-559457 (SB), a non-peptidyl hydrazone class of thrombopoietin receptor (Mpl) agonist, revealed toxicity towards human leukemia cells. Anti-proliferative effects followed by significant, non-apoptotic, cell death within 72 hours occurred in 24/26 AML, 0/6 ALL, and 3/6 CML patient samples exposed to SB, but not recombinant human thrombopoietin (rhTpo), in liquid suspension culture. Further investigation revealed increased phosphorylation of p70S6/S6 kinases in SB, but not in rhTpo, treated cells. Expression profiling of cells exposed to SB vs rhTpo revealed statistically significant, ~2-fold changes in GAPDH and REDD1 gene expression, confirmed by QRT-PCR. These genes, induced in energy or hypoxia stressed cells, have been implicated in cell death pathways, and may provide important clues to the mechanism of SB induced, leukemic cell death. These results suggest that nonpeptidyl, hydrazone class Mpl agonists may be clinically useful anti-leukemic agents by virtue of their combined thrombopoietic and anti-leukemic effects. Experiment Overall Design: Primary cells collected from 5 patients with acute myeloid leukemia (AML) were stimulated stimulated with MPL receptor agonist (SB559457) or recombinant human Tpo (rhTpo) for 6 hours. Next, RNA was isolated from these cells. RNA was used for gene profile analyis to compare genes regulated in AML cells by SB559457 verus rhTpo. For each sample half of the cells were stimulated with Mpl agonist and half with rhTpo.

2009-11-10 | E-GEOD-18673 | biostudies-arrayexpress

Gene expression in murine leukemic B cells treated with leukemic extracellular vesicles

Project description:Gene expression in murine leukemic B cells treated with leukemic extracellular vesicles

| PRJNA789946 | ENA

3' UTR RNA-sequencing of humanized EGFR-mutant PC9 cell line xenografts treated with osimertinib/vehicle of RIG-I agonist IVT4/unspecific control IVT-GAC

Project description:Immunocompromised mice were inoculated with human lung adenocarcinoma cell line PC9 and with human PBMCs. Tumors were treated with osimertinib/vehicle of RIG-I agonist IVT4/unspecific control IVT-GAC to assess response.

2021-07-20 | E-MTAB-9891 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data